Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel

Am J Kidney Dis. 2021 Jun;77(6):990-992. doi: 10.1053/j.ajkd.2020.08.017. Epub 2020 Oct 22.

Authors

Meghan D Lee¹, Ian A Strohbehn¹, Harish S Seethapathy¹, Nifasha Rusibamayila¹, Keagan S Casey², Shruti Gupta³, David E Leaf³, Matthew J Frigault², Meghan E Sise⁴

Affiliations

¹ Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
² Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
³ Division of Nephrology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.
⁴ Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA. Electronic address: msise@mgh.harvard.edu.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Acute Kidney Injury / epidemiology*
Adult
Aged
Female
Humans
Immunotherapy, Adoptive*
Male
Middle Aged
Receptors, Antigen, T-Cell / therapeutic use*
Receptors, Chimeric Antigen / therapeutic use*
Retrospective Studies

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen
tisagenlecleucel

Grants and funding